{{Drugbox
| verifiedrevid = 454826769
| IUPAC_name = (R)-(1-((1-methylpiperidin-2-yl)methyl)-1H-indol-3-yl)(naphthalen-1-yl)methanone
| image = AM-1220_structure.png
| width = 200

<!--Clinical data-->
| tradename =  
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = S9
| legal_CA = Schedule II
| legal_DE = Anlage II
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
| legal_NZ = Temporary Class 
| legal_status =
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 137642-54-7
| CAS_supplemental = (racemic) <br /> 134959-64-1 ((R) enantiomer)
| ATC_prefix =  
| ATC_suffix =  
| PubChem = 9929889
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 26231035

<!--Chemical data-->
| C=26 | H=26 | N=2 | O=1 
| molecular_weight = 382.497 g/mol
| smiles = O=C(C1=CC=CC2=C1C=CC=C2)C3=CN(C[C@@H]4N(C)CCCC4)C5=CC=CC=C53
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C26H26N2O/c1-27-16-7-6-11-20(27)17-28-18-24(22-13-4-5-15-25(22)28)26(29)23-14-8-10-19-9-2-3-12-21(19)23/h2-5,8-10,12-15,18,20H,6-7,11,16-17H2,1H3/t20-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = URKVBEKZCMUTQC-HXUWFJFHSA-N
}}

'''AM-1220''' is a drug that acts as a potent and moderately selective [[agonist]] for the [[cannabinoid receptor]] [[Cannabinoid receptor 1|CB<sub>1</sub>]], with around 19x selectivity for CB<sub>1</sub> over the related [[Cannabinoid receptor 2|CB<sub>2</sub>]] receptor.<ref name="WO 2001 28557 A1">{{Ref patent2 |country= WO |number= 200128557 |status= granted |title= Cannabimimetic indole derivatives |pubdate= 2001-04-26 |gdate= 2001-06-07 |pridate= 1999-10-18 |inventor= Makriyannis A, Deng H }}</ref> It was originally invented in the early 1990s by a team led by Thomas D'Ambra at [[Sterling Winthrop]],<ref name="US 5068234">{{Ref patent2 |country= US |number= 5068234 |status= granted |title= 3-arylcarbonyl-1-(C-attached-N-heteryl)-1H-indoles |gdate= 1991-11-26 |pridate= 1990-02-26 |inventor= Thomas E. D'Ambra ''et al.'' }}</ref> but has subsequently been researched by many others, most notably the team led by [[Alexandros Makriyannis]] at the [[University of Connecticut]]. The (piperidin-2-yl)methyl side chain of AM-1220 contains a stereocenter, so there are two [[enantiomer]]s with quite different potency, the (R) enantiomer having a [[Dissociation constant|K<sub>i</sub>]] of 0.27nM at CB<sub>1</sub> while the (S) enantiomer has a much weaker K<sub>i</sub> of 217nM.<ref>{{Cite journal | last1 = D'ambra | first1 = T. | doi = 10.1016/0960-894X(95)00560-G | title = C-Attached aminoalkylindoles: potent cannabinoid mimetics | journal = Bioorganic & Medicinal Chemistry Letters | volume = 6 | pages =  17–22| year = 1996 | pmid =  | pmc = | issue=1}}</ref> A number of related compounds are known with similar potent cannabinoid activity, with modifications such as substitution of the indole ring at the 2- or 6- positions, the naphthoyl ring substituted at the 4- position or replaced by substituted benzoyl rings or other groups, or the 1-(N-methylpiperidin-2-ylmethyl) group replaced by similar heterocyclic groups such as N-methylpyrrolidin-2-ylmethyl or N-methylmorpholin-3-ylmethyl.<ref name=liganDesign>{{Cite thesis |type=PhD. Dissertation |title=Design and synthesis of selective cannabinoid receptor ligands: Aminoalkylindole and other heterocyclic analogs |url=http://search.proquest.com/docview/304624325 |author=Hongfeng Deng |year=2000 |publisher=University of Connecticut }}</ref><ref>{{Cite journal | last1 = Willis | first1 = P. G. | last2 = Pavlova | first2 = O. A. | last3 = Chefer | first3 = S. I. | last4 = Vaupel | first4 = D. B. | last5 = Mukhin | first5 = A. G. | last6 = Horti | first6 = A. G. | doi = 10.1021/jm0502743 | title = Synthesis and Structure−Activity Relationship of a Novel Series of Aminoalkylindoles with Potential for Imaging the Neuronal Cannabinoid Receptor by Positron Emission Tomography | journal = Journal of Medicinal Chemistry | volume = 48 | issue = 18 | pages = 5813–22 | year = 2005 | pmid =  
16134948| pmc = }}</ref><ref name="US 7820144">{{Ref patent2 |country= US |number= 7820144 |status= granted |title= Receptor selective cannabimimetic aminoalkylindoles |gdate= 2010-10-26 |pridate= 2007-01-05 |inventor= Alexandros Makriyannis, ''et al.'' }}</ref> AM-1220 was first detected as an ingredient of [[synthetic cannabis]] smoking blends in 2010.<ref>[http://www.drugs.ie/downloadDocs/HS_ID_Poster_714-823.pdf Head Shop ‘Legal Highs’ Active Constituents Identification Chart (July - August 2010)]</ref>

[[Image:AM1220heterocycles.png|300px|thumb|none|Related 1-(N-methylpyrrolidin-2-ylmethyl) and 1-(N-methylmorpholin-3-ylmethyl) derivatives]]

==Legal Status==

As of October 2015 AM-1220 is a controlled substance in China.<ref>{{cite web | url=http://www.sfda.gov.cn/WS01/CL0056/130753.html | title=关于印发《非药用类麻醉药品和精神药品列管办法》的通知 | publisher=China Food and Drug Administration | date=27 September 2015 | language=Chinese | accessdate=1 October 2015}}</ref>

==See also==
* [[A-834,735]]
* [[AM-1221]]
* [[AM-1248]]
* [[AM-2201]]
* [[AM-2233]]
* [[Cannabipiperidiethanone]]

==References==
{{reflist}}

{{Cannabinoids}}

[[Category:Cannabinoids]]
[[Category:Naphthoylindoles]]
[[Category:AM cannabinoids]]
[[Category:Aminoalkylindoles]]
[[Category:Piperidines]]
[[Category:Designer drugs]]
[[Category:CB1 receptor agonists]]
[[Category:CB2 receptor agonists]]